Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double...
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific...
-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the...
Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor...
Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These...
SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a novel...
uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters...
Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) --...
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma...
Supporting discovery through screening, the X9 is the only system integrating real-time PCR and NGS library preparationSOUTH SAN FRANCISCO, Calif.,...
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the...
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that...
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with...
Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease...
Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell...
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid...
In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection,...
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
In the first quarter of 2023, Mendus continued on the path set out by the key progress realized at the...